Notable Labs Pauses Implementation of Cancer Drug Volasertib Study, Announces Layoffs

Dow Jones

Sep 20, 2024

By Stephen Nakrosis

Notable Labs said it is pausing implementation of the planned Phase 2 study of cancer drug Volasertib in relapsed/refractory acute myeloid leukemia.

The biotechnology company also said Thursday it will reduce its workforce and outside consultants by approximately 65%.

The decisions, which will conserve cash, follow the board's approval of a streamlined operating plan which includes exploring strategic alternatives, according to the company.

Notable expects to incur about $100,000 in total charges related to the reduction in force.

Following the announcement, the company's shares rose in the after-hours market, gaining 5% to trade at 50 cents. They closed the day's regular trading session at 47 cents, gaining 5.5%.

Last month, the company named Joseph Wagner as its interim chief executive. Wagner succeeded Thomas Bock, who will continue to serve as a consultant.

Notable has initiated a search for a permanent CEO.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

September 19, 2024 17:44 ET (21:44 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2468910636"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2468910636\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2468910636?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-20 05:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2468910636","market":"sg","top_or_hot":-1,"title":"Notable Labs Pauses Implementation of Cancer Drug Volasertib Study, Announces Layoffs","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  Notable Labs said it is pausing implementation of the planned Phase 2 study of cancer drug Volasertib in relapsed/refractory acute myeloid leukemia. \n</p>\n<p>\n  The biotechnology company also said Thursday it will reduce its workforce and outside consultants by approximately 65%. \n</p>\n<p>\n  The decisions, which will conserve cash, follow the board's approval of a streamlined operating plan which includes exploring strategic alternatives, according to the company. \n</p>\n<p>\n  Notable expects to incur about $100,000 in total charges related to the reduction in force. \n</p>\n<p>\n  Following the announcement, the company's shares rose in the after-hours market, gaining 5% to trade at 50 cents. They closed the day's regular trading session at 47 cents, gaining 5.5%. \n</p>\n<p>\n  Last month, the company named Joseph Wagner as its interim chief executive. Wagner succeeded Thomas Bock, who will continue to serve as a consultant. \n</p>\n<p>\n  Notable has initiated a search for a permanent CEO. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 19, 2024 17:44 ET (21:44 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Notable Labs Pauses Implementation of Cancer Drug Volasertib Study, Announces Layoffs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNotable Labs Pauses Implementation of Cancer Drug Volasertib Study, Announces Layoffs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-09-20 05:44</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  Notable Labs said it is pausing implementation of the planned Phase 2 study of cancer drug Volasertib in relapsed/refractory acute myeloid leukemia. \n</p>\n<p>\n  The biotechnology company also said Thursday it will reduce its workforce and outside consultants by approximately 65%. \n</p>\n<p>\n  The decisions, which will conserve cash, follow the board's approval of a streamlined operating plan which includes exploring strategic alternatives, according to the company. \n</p>\n<p>\n  Notable expects to incur about $100,000 in total charges related to the reduction in force. \n</p>\n<p>\n  Following the announcement, the company's shares rose in the after-hours market, gaining 5% to trade at 50 cents. They closed the day's regular trading session at 47 cents, gaining 5.5%. \n</p>\n<p>\n  Last month, the company named Joseph Wagner as its interim chief executive. Wagner succeeded Thomas Bock, who will continue to serve as a consultant. \n</p>\n<p>\n  Notable has initiated a search for a permanent CEO. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 19, 2024 17:44 ET (21:44 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2468910636","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2468910636","pubTimestamp":1726782240,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"The biotechnology company also said Thursday it will reduce its workforce and outside consultants by approximately 65%.The decisions, which will conserve cash, follow the board's approval of a streamlined operating plan which includes exploring strategic alternatives, according to the company.Notable expects to incur about $100,000 in total charges related to the reduction in force.Following the announcement, the company's shares rose in the after-hours market, gaining 5% to trade at 50 cents. They closed the day's regular trading session at 47 cents, gaining 5.5%.Last month, the company named Joseph Wagner as its interim chief executive. Wagner succeeded Thomas Bock, who will continue to serve as a consultant.Notable has initiated a search for a permanent CEO.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","NTBL":"Notable Labs Inc."},"translate_title":"Notable Labs暂停实施抗癌药物Volasertib研究，宣布裁员","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTBL":0.9},"content_text":"By Stephen Nakrosis \n\n\n \n\n\n  Notable Labs said it is pausing implementation of the planned Phase 2 study of cancer drug Volasertib in relapsed/refractory acute myeloid leukemia. \n\n\n  The biotechnology company also said Thursday it will reduce its workforce and outside consultants by approximately 65%. \n\n\n  The decisions, which will conserve cash, follow the board's approval of a streamlined operating plan which includes exploring strategic alternatives, according to the company. \n\n\n  Notable expects to incur about $100,000 in total charges related to the reduction in force. \n\n\n  Following the announcement, the company's shares rose in the after-hours market, gaining 5% to trade at 50 cents. They closed the day's regular trading session at 47 cents, gaining 5.5%. \n\n\n  Last month, the company named Joseph Wagner as its interim chief executive. Wagner succeeded Thomas Bock, who will continue to serve as a consultant. \n\n\n  Notable has initiated a search for a permanent CEO. \n\n\n \n\n\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 19, 2024 17:44 ET (21:44 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}